BY 101298
Alternative Names: BY-101298Latest Information Update: 11 Jul 2024
At a glance
- Originator Chengdu Baiyu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Jun 2024 Chengdu Baiyu Pharmaceutical plans to launch BY 101298 in 2026 (Chengdu Baiyu Pharmaceutical pipeline, June 2024)
- 31 May 2024 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 25 Apr 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (PO) (NCT06462716)